Sertraline Citrate

DUBLIN, July 26, 2023 /PRNewswire/ -- The "Obsessive-Compulsive Disorder (OCD) Market Insights, Epidemiology, and Forecast to 2032" report has been added to ResearchAndMarkets.com's offering. Obsessive-Compulsive Disorder (OCD) Market: In-Depth Analysis and Treatment Landscape Obsessive-Compulsive Disorder (OCD) is a mental health disorder characterized by intrusive thoughts, images, or impulses causing anxiety, and repetitive behaviors aimed at reducing that anxiety. It follows a chronic course, often leading to years of suffering before seeking treatment. The DSM-5 diagnostic criteria for OCD remain largely unchanged from DSM-IV, with two specifiers added: insight and tic-related disorder. Market Overview: In 2022, there were approximately 12,082,000 total prevalent cases of OCD in the 7 major markets (7MM). Most diagnosed cases are severe, with 50% classified as severe, 35% as moderate, and 15% as mild. The United States accounted for the highest number of diagnosed cases in 2022, approximately 2,156,000 cases, and the OCD market size in the US was around USD 600 million. Treatment Landscape: Treatment for OCD involves building a therapeutic alliance, psychoeducation, and utilizing psychological and/or pharmacological approaches. Selective Serotonin Reuptake Inhibitors (SSRIs) are the most commonly prescribed medications for OCD, with drugs like sertraline, fluoxetine, and fluvoxamine being popular choices. Emerging Therapies: Troriluzole, developed by Biohaven Pharmaceuticals, is a promising drug in the OCD treatment landscape. It is a glutamate-release inhibitor and has shown encouraging results in clinical trials. If successful, troriluzole is expected to bring major changes in the OCD treatment landscape, offering safer and more effective options. Market Outlook: The total market size of OCD in the 7MM is projected to increase at a CAGR of ~5%, reaching approximately USD 1,000 million by 2032. The growth is driven by an increase in the prevalent pool of the disease and the launch of new therapies. Key Highlights: Obsessive-compulsive disorder (OCD) has been given increased attention in DSM-5, receiving its chapter. However, the diagnostic criteria for OCD in DSM-5 remain largely the same as in DSM-IV, requiring either obsessions or compulsions. The major change in the DSM-5 criteria for OCD is the addition of two specifiers for this diagnosis: insight and tic-related disorder. OCD symptoms may be present for years before treatment is sought, and those affected often suffer in silence. The disease follows a chronic waxing and waning course where 15% of patients have deterioration, and 5% have episodes with inter-episode recovery. The diagnosis of obsessive-compulsive disorder (OCD) is established by the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnostic criteria, while the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is used for the assessment of its severity. In 2022, there were ~12,082,000 total prevalent cases of obsessive-compulsive disorder (OCD) in the 7MM. Most of the diagnosed cases of Obsessive Compulsive Disorder (OCD) are severe, with around 15%, 35%, and 50% of individuals having mild, moderate, and severe OCD, respectively. The United States accounted for the highest number of diagnosed cases of OCD in the 7MM, i.e., ~2,156,000 cases in 2022. In 2022, the market size of OCD was the highest in the US among the 7MM, accounting for approximately USD 600 million. Treatment of OCD comprises several components, starting with building a therapeutic alliance with the patient and psychoeducation. Then psychological and/or pharmacological approaches, and, for patients with treatment-resistant OCD, neuromodulation, and neurosurgery. The NICE guidelines propose CBT as the treatment of choice for OCD and body dysmorphic disorder due to the rigorous research invested into CBT for OCD and the effectiveness of treatment. The expected launch of troriluzole (Biohaven Pharmaceuticals) by 2027 is set to bring major changes in the treatment landscape of OCD, bringing in safer and more effective treatment options for OCD patients. Selective Serotonin Reuptake Inhibitors (SSRIs) are the most popular form of treatment for OCD, which works by increasing serotonin levels in the brain. Some widely used medications for the treatment of OCD are citalopram (CELEXA, CIPRAMIL), escitalopram (CIPRALEX, LEXAPRO), fluoxetine (PROZAC), fluvoxamine (FAVERIN, LUVOX), paroxetine (PAXIL, SEROXAT), sertraline (LUSTRAL, ZOLOFT). If these medications fail to work, a non-selective SRI may be prescribed. However, because it affects neurotransmitters in the brain other than just serotonin, there are more side effects, and therefore it is usually not a first-choice medication for treating OCD. The non-selective SRI most commonly used for treating OCD is clomipramine (ANAFRANIL). The generic alternatives of the approved marketed assets for OCD, such as sertraline hydrochloride, fluoxetine, fluvoxamine, clomipramine, etc., entered the market from 1996-2006. Key Topics Covered 1. Key Insights 2. Report Introduction 3. OCD Market Overview at a Glance 4. Executive Summary of Obsessive-compulsive Disorder (OCD) 5. Epidemiology and Market Methodology 6. Disease Background and Overview 7. Epidemiology and Patient Population 8. Patient Journey 9. Marketed Therapies 10. Emerging Therapies 11. OCD: The 7MM Market Analysis 12. KOL Views 13. SWOT Analysis 14. Unmet needs 15. Market Access and Reimbursement 16. Appendix For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

DUBLIN, July 20, 2023 /PRNewswire/ -- The "Post-Traumatic Stress Disorder Therapeutics Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This comprehensive report provides critical information for strategists, marketers, and senior management to assess the post-traumatic stress disorder (PTSD) therapeutics market. The market is projected to grow from $3.15 billion in 2022 to $3.42 billion in 2023, with a compound annual growth rate (CAGR) of 8.72%. Furthermore, the market is expected to reach $4.82 billion by 2027, exhibiting a CAGR of 8.96%. Major players in the post-traumatic stress disorder therapeutics market include Novartis AG, Pfizer Inc., Bionomics Ltd., Apotex Inc., GlaxoSmithKline PLC., Otsuka Pharmaceutical Co. Ltd., Eli Lilly and Company, Aurobindo Pharma Limited, Merck KGaA, Sun Pharmaceuticals Pvt Ltd., Strategic Behavioral Health, Jazz Pharmaceuticals, Bionomics, Behavioral Health Network Inc., AstraZeneca PLC., Apotex Inc., Prometheon Pharma LLC., Ligand Pharmaceuticals Incorporated, Lycera Corp., and JSC Valenta Pharm. Reasons to Purchase: Gain a comprehensive global perspective with detailed coverage of 50+ geographies. Understand the market's response to COVID-19 and its impact as the virus abates. Assess the direct and indirect effects of the Russia-Ukraine war on agriculture, energy, mineral commodity supply, and the market. Measure the influence of high global inflation on market growth. Develop regional and country-specific strategies based on localized data and analysis. Identify investment opportunities in growth segments. Outperform competitors using forecast data and insights into market drivers and trends. Understand customer dynamics based on the latest market shares. Benchmark performance against key competitors. Support internal and external presentations with reliable high-quality data and analysis. Post-traumatic stress disorder therapeutics encompass treatments used to address PTSD, a mental health condition triggered by experiencing or witnessing traumatic events. These therapies aim to improve patients' cognitive abilities, physical activity, and regain a sense of control over their lives. Treatment modalities for PTSD include medication, therapy, self-care, and nutrition. The main drug categories in PTSD therapeutics include antidepressants, anti-anxiety medications, antihypertensive drugs, monoamine oxidase inhibitors (MAOIs), antipsychotics or second-generation antipsychotics (SGAs), beta-blockers, and others (such as benzodiazepines). Antidepressants are used to manage addiction and treat conditions like major depressive disorder, anxiety disorders, and chronic pain. Therapeutic services cater to different age groups, including pediatric, geriatric, and adults, and are provided by mental health centers, hospitals, outpatient clinics, and other facilities. Strategic collaborations, funding, and investments are emerging trends in the PTSD therapeutics market, with major companies forging partnerships and investing in other organizations to strengthen their market position. For example, in January 2022, Professor Dan Lubman AM, Dr. Shalini Arunogiri, and Dr. Paul Liknaitzky of Monash University received over $1.9 million to study the effectiveness of MDMA-assisted psychological treatment for alcohol use disorder (AUD) and PTSD. This research initiative is part of seven clinical studies under the Medical Research Future Fund (MRFF), supported by the Australian Federal Government, to explore the use of potentially groundbreaking combination therapies for debilitating mental illnesses. North America dominated the post-traumatic stress disorder therapeutics market in 2022, while Asia-Pacific is expected to witness the highest growth during the forecast period. The regions covered in the report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. Key countries analyzed in the report include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The increasing burden of PTSD cases worldwide is expected to drive the growth of the post-traumatic stress disorder therapeutics market. PTSD is a disorder that develops in individuals who have experienced or witnessed scary, shocking, or dangerous events. Therapeutic interventions, including psychotherapy and medication, play a crucial role in helping individuals regain a sense of control over their lives. According to the United States Department of Veterans Affairs, nearly 8 million Americans were estimated to be suffering from PTSD in 2021. The rising burden of PTSD cases underscores the need for effective therapeutics and fuels the growth of the post-traumatic stress disorder therapeutics market. The post-traumatic stress disorder therapeutics market includes revenues earned by entities providing treatment services such as psychotherapy, medication, and combination therapies. The market value comprises the value of related goods and services sold by the service providers. The market also includes sales of specific drugs used in PTSD treatment, such as Sertraline, Paroxetine, and Fluoxetine. Key Topics Covered: 1. Executive Summary 2. Post-Traumatic Stress Disorder Therapeutics Market Characteristics 3. Post-Traumatic Stress Disorder Therapeutics Market Trends And Strategies 4. Post-Traumatic Stress Disorder Therapeutics Market - Macro Economic Scenario 4.1. COVID-19 Impact On Post-Traumatic Stress Disorder Therapeutics Market 4.2. Ukraine-Russia War Impact On Post-Traumatic Stress Disorder Therapeutics Market 4.3. Impact Of High Inflation On Post-Traumatic Stress Disorder Therapeutics Market 5. Post-Traumatic Stress Disorder Therapeutics Market Size And Growth 5.1. Global Post-Traumatic Stress Disorder Therapeutics Historic Market, 2017-2022, $ Billion 5.1.1. Drivers Of The Market 5.1.2. Restraints On The Market 5.2. Global Post-Traumatic Stress Disorder Therapeutics Forecast Market, 2022-2027F, 2032F, $ Billion 5.2.1. Drivers Of The Market 5.2.2. Restraints On the Market 6. Post-Traumatic Stress Disorder Therapeutics Market Segmentation 6.1. Global Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion Antidepressants Anti-Anxiety Antihypertensive Monoamine Oxidase (MAOs) Antipsychotics Or Second Generation Antipsychotics (SGOs) Beta-Blockers Other Classes 6.2. Global Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion Pediartic Geriatric Adult 6.3. Global Post-Traumatic Stress Disorder Therapeutics Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion Mental Health Center Hospitals Outpaitent Clinics Other End Users 7. Post-Traumatic Stress Disorder Therapeutics Market Regional And Country Analysis 7.1. Global Post-Traumatic Stress Disorder Therapeutics Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion 7.2. Global Post-Traumatic Stress Disorder Therapeutics Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets